From: Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study
Age (years) | 55.61 ± 2.32 (45–71 years) |
Sex (male/female) | 13/0 |
Duration of CSCR symptoms prior to eplerenone therapy (months) | 17.40 ± 3.9 (4–36 months) |
Total number of patients with prior treatments | 5/13a |
Photodynamic laser therapy (PDT) | 3/13 |
Focal laser therapy | 2/13 |
Intravitreal bevacizumab | 3/13 |